Saihe Medical develops pan-vascular active interventional products including a coronary intravascular lithotripsy system, peripheral intravascular lithotripsy system, intracardiac ultrasound imaging system and intravascular ultrasound. Founded in April 2020 and headquartered in Shenzhen, the company says it has overcome overseas high-end medical device technical barriers and independently developed these innovative products. Saihe plans to form a 4–6 product matrix by the end of 2024 and offer integrated solutions across coronary, peripheral, structural heart disease and electrophysiology indications. The company intends to simplify procedures, improve surgical efficiency and reduce medical costs to deliver safer, more accessible care. Saihe is moving toward product commercialization and is accelerating market launches to reach more patients. It is also pursuing global patents and planning overseas registration clinical programs.

Total raised

$27M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2023